Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a report released on Tuesday,Benzinga reports. They currently have a $5.00 target price on the stock.

Other analysts have also issued research reports about the stock. Benchmark restated a “speculative buy” rating and set a $3.00 target price on shares of Hoth Therapeutics in a research report on Friday, October 11th. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price objective on shares of Hoth Therapeutics in a research report on Monday, November 4th.

Hoth Therapeutics Price Performance

Shares of NASDAQ HOTH opened at $2.28 on Tuesday. The firm’s 50-day moving average is $0.86 and its two-hundred day moving average is $0.85. The company has a market capitalization of $15.74 million, a PE ratio of -1.73 and a beta of 0.75. Hoth Therapeutics has a 12-month low of $0.58 and a 12-month high of $3.80.

Hoth Therapeutics (NASDAQ:HOTH) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.01). On average, analysts forecast that Hoth Therapeutics will post -1.18 EPS for the current fiscal year.

Institutional Investors Weigh In On Hoth Therapeutics

A hedge fund recently bought a new stake in Hoth Therapeutics stock. Virtu Financial LLC bought a new stake in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned approximately 0.47% of Hoth Therapeutics at the end of the most recent quarter. 7.08% of the stock is owned by hedge funds and other institutional investors.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.